%0 Journal Article
%T Ceacam1 Separates Graft-versus-Host-Disease from Graft-versus-Tumor Activity after Experimental Allogeneic Bone Marrow Transplantation
%A Sydney X. Lu
%A Lucy W. Kappel
%A Anne-Marie Charbonneau-Allard
%A Ren¨Ĥe Atallah
%A Amanda M. Holland
%A Claire Turbide
%A Vanessa M. Hubbard
%A Jimmy A. Rotolo
%A Marsinay Smith
%A David Suh
%A Christopher King
%A Uttam K. Rao
%A Nury Yim
%A Johanne L. Bautista
%A Robert R. Jenq
%A Olaf Penack
%A Il-Kang Na
%A Chen Liu
%A George Murphy
%A Onder Alpdogan
%A Richard S. Blumberg
%A Fernando Macian
%A Kathryn V. Holmes
%A Nicole Beauchemin
%A Marcel R. M. van den Brink
%J PLOS ONE
%D 2012
%I Public Library of Science (PLoS)
%R 10.1371/journal.pone.0021611
%X Allogeneic bone marrow transplantation (allo-BMT) is a potentially curative therapy for a variety of hematologic diseases, but benefits, including graft-versus-tumor (GVT) activity are limited by graft-versus-host-disease (GVHD). Carcinoembryonic antigen related cell adhesion molecule 1 (Ceacam1) is a transmembrane glycoprotein found on epithelium, T cells, and many tumors. It regulates a variety of physiologic and pathological processes such as tumor biology, leukocyte activation, and energy homeostasis. Previous studies suggest that Ceacam1 negatively regulates inflammation in inflammatory bowel disease models.
%U http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0021611